Article Text

Download PDFPDF
Dogs
Prolonged survival of a 7-year-old vizsla with histiocytic sarcoma affecting the spinal cord and protein-losing nephropathy after lomustine treatment
  1. Ivona Orgonikova1,
  2. Marco Rosati2,
  3. Nicki Reed1,3,
  4. Simon Tappin4 and
  5. Viktor Palus5
  1. 1Neurology and Neurosurgery, Wear Referrals Veterinary Hospital, Stockton-on-Tees, UK
  2. 2Institute of Veterinary Pathology/Neuropathology, Ludwig-Maximilians-Universitat Munchen, Munchen, Germany
  3. 3Veterinary Specialists Scotland, Livingston, UK
  4. 4Small Animal Internal Medicine, Dick White Referrals, Newmarket, UK
  5. 5NeuroVet, Trencin, Slovakia
  1. Correspondence to Ivona Orgonikova; iorgonikova{at}gmail.com

Abstract

A 7-year-old male entire vizsla, diagnosed with protein-losing nephropathy (PLN) one month previously, presented with lumbar hyperaesthesia. MRI of the lumbar spine revealed an extradural mass at the level of L3 vertebra. Most of the mass was surgically excised during left-sided pediculectomy at L3 and left-sided L2-L3 mini-hemilaminectomy. Histopathology revealed a moderately proliferative, lymphocyte/plasmacyte-rich, mesenchymo-invasive localised histiocytic sarcoma affecting the spinal cord. Chemotherapy with lomustine (1-(2-chloroethyl)-3-cyclohexyl-1-nitrosurea) was commenced for treatment of the histiocytic sarcoma and during therapy the persistent proteinuria resolved, having previously only shown an improvement with symptomatic treatment. The dog survived 881 days after diagnosis, which is exceptional in cases of histiocytic sarcomas affecting CNS.

  • histiocytic sarcoma
  • proteinuria
  • spinal cord
View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors Dr Gerard te Lintelo and Dr Lorenzo Mari conttributed in final completition of this work. All authors discussed the results and commented on the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement All data relevant to the study are included in the article.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.